ABUS - Arbutus Biopharma Corp

https://www.arbutusbio.com

Buy Momentum: Bearish

Recent News

Is Arbutus Biopharma ( ABUS ) Stock Outpacing Its Medical Peers This Year?

Zacks Commentary • 2 weeks ago • score: 0.51

Here is how Arbutus Biopharma (ABUS) and Armata Pharmaceuticals, Inc. (ARMP) have performed compared to their sector so far this year.

Bullish

Is Aquestive Therapeutics ( AQST ) Stock Outpacing Its Medical Peers This Year?

Zacks Commentary • 1 month ago • score: 0.23

Here is how Aquestive Therapeutics (AQST) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Range-Bound

As of 2025-09-09 (Snapshot)

Arbutus Biopharma Corporation, a biopharmaceutical company, is dedicated to the discovery, development, and commercialization of a cure for patients with chronic hepatitis B virus (HBV) infection in the United States. The company is headquartered in Warminster, Pennsylvania.

52W High

$5.10

52W Low

$2.71

MA Status:

50D: Above 200D: Above

Beta (~1 neutral, <0.9 lower risk)

1.01

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-5.64

EV/Revenue (<3 favorable)

51.16

P/S (TTM) (<3 favorable)

57.45

P/B (<3 favorable)

10.67

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

21.87%

Institutions (25–75% balanced)

62.58%

Shares Outstanding

191,699,000

Float

126,050,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

15,416,000

Gross Profit (TTM)

-37,390,000

EPS (TTM)

-0.29

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

0.18%

ROE (TTM) (>15% strong)

-0.53%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

5.22

Momentum

Bearish momentum

Value

0.3760

0.3789

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025